- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AN100226 | anti-alpha4 integrin | anti-VLA4 | Tysabri®
natalizumab is an approved drug (FDA (2004), EMA (2006))
Compound class: Antibody
Comment: Natalizumab was the first migration-inhibitory biological drug to be approved for inflammatory diseases.
Targeting cell migration-related molecules in immune conditions (and cancer) is regarded as a significant new focus for the development of novel anti-inflammatory therapeutics .
The design and synthesis of this antibody is described in , but the article is not open access.
View more information in the IUPHAR Pharmacology Education Project: natalizumab
|Natalizumab targets α4-containing intergrins, including the α4β1 lymphocyte homing receptor.|
|Approved drug for CD.|
|Approved for the treatment of relapsing forms of multiple sclerosis.|